Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis
Overview
Affiliations
Background Cardio-oncology is a clinical discipline focused primarily on the early detection of anticancer therapy-related cardiomyopathy. However, there is growing evidence that the direct adverse consequences extend beyond the myocardium to affect the vasculature, but this evidence remains limited. In addition, there remains a paucity of clinically based strategies for monitoring vascular toxicity in these patients. Importantly, arterial stiffness is increasingly recognized as a surrogate end point for cardiovascular disease and may be an important vascular outcome to consider. Therefore, the aim of this systematic review and meta-analysis was to summarize evidence of increased arterial stiffening with anticancer therapy and evaluate the effect of treatment modifiers. Methods and Results A total of 19 longitudinal and cross-sectional studies that evaluated arterial stiffness both during and following anticancer therapy were identified using multiple databases. Two separate analyses were performed: baseline to follow-up (12 studies) and control versus patient groups (10 studies). Subgroup analysis evaluated whether stiffness differed as a function of treatment type and follow-up time. Standard mean differences and mean differences were calculated using random effect models. Significant increases in arterial stiffness were identified from baseline to follow-up (standard mean difference, 0.890; 95% CI, 0.448-1.332; <0.0001; mean difference, 1.505; 95% CI, 0.789-2.221; ≤0.0001) and in patient versus control groups (standard mean difference, 0.860; 95% CI, 0.402-1.318; =0.0002; mean difference, 1.437; 95% CI, 0.426-2.448; =0.0052). Subgroup analysis indicated differences in arterial stiffness between anthracycline-based and non-anthracycline-based therapies (standard mean difference, 0.20; 95% CI, 0.001-0.41; =0.048), but not follow-up time. Conclusions Significant arterial stiffening occurs following anticancer therapy. Our findings support the use of arterial stiffness as part of a targeted vascular imaging strategy for the identification of early cardiovascular injury during treatment and for the detection of long-term cardiovascular injury into survivorship.
External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations.
Scheuermann B, Brown A, Colburn T, Hakeem H, Chow C, Ade C JAMA Netw Open. 2024; 7(10):e2438311.
PMID: 39392632 PMC: 11470385. DOI: 10.1001/jamanetworkopen.2024.38311.
Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer.
Todorova V, Azhar G, Stone A, Malapati S, Che Y, Zhang W Int J Mol Sci. 2024; 25(17).
PMID: 39273682 PMC: 11395913. DOI: 10.3390/ijms25179735.
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part: State-of-the-Art Review.
Dillon H, Foulkes S, Baik A, Scott J, Touyz R, Herrmann J JACC CardioOncol. 2024; 6(4):496-513.
PMID: 39239327 PMC: 11372306. DOI: 10.1016/j.jaccao.2024.04.006.
Rankin S, Fountain C, Gemmell A, Quinn D, Henderson A, McClure J bioRxiv. 2024; .
PMID: 38895275 PMC: 11185566. DOI: 10.1101/2024.05.30.596741.
Lefferts E, Lee D J Am Heart Assoc. 2024; 13(12):e032886.
PMID: 38842278 PMC: 11255755. DOI: 10.1161/JAHA.123.032886.